focus -WSS

focus

author：focus 2025-09-28 08:13:16 - browse：28388

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Protect nursing home residents from future pandemics

WSS

Medical students need to learn the potent medicine of empathy

Bird flu makes raw milk dangerous to consume, mouse study finds

David Ricks of Eli Lilly: best biopharma CEO of 2023

Bird flu makes raw milk dangerous to consume, mouse study finds

Virtual care provider acquires bankrupt Pear's prescription apps

Prime Medicine, Myeloid Therapeutics clash over genome

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

What does generative AI mean for health care? We asked experts

Albert Bourla of Pfizer: worst biopharma CEO of 2023

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Stroke rates rising, especially in working

Walensky prepares to leave CDC — and Congress — behind

Drinking less cuts risk of oral cavity, esophageal cancer: Report

BioMarin wins approval for gene therapy to treat hemophilia A

Hospitals need to get ahead of regulations on climate change

The high cost of giving birth even with insurance

Can sheer will power keep patients alive in their dying hours?

knowledge

Keeping primary care docs in field isn't impossible, says AAFP CEO

Carvykti CAR

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Why some fertility treatments produce more boy babies

Carvykti CAR

Readout Newsletter: The latest on Moderna, Apellis, and Merck

entertainment

Wikipedia

explore

focus